(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Curis, Citi Trends, and Aspen Group.

Rank Financial Asset Price Change Updated (EST)
1 Curis (CRIS) 0.82 17.2% 2022-10-04 19:41:14
2 Citi Trends (CTRN) 17.57 11.06% 2022-10-04 21:13:06
3 Aspen Group (ASPU) 0.43 9.93% 2022-10-05 14:32:20
4 Eagle Pharmaceuticals (EGRX) 26.99 8.05% 2022-10-05 07:09:05
5 Cytosorbents Corporation (CTSO) 1.51 7.86% 2022-10-04 21:14:06
6 Bionano Genomics (BNGO) 2.20 7.6% 2022-10-05 14:45:42
7 8×8 (EGHT) 3.71 7.23% 2022-10-05 07:06:13
8 Schlumberger (SLB) 41.89 7.08% 2022-10-05 14:49:24
9 Cavco Industries (CVCO) 228.84 6.66% 2022-10-04 22:41:14
10 Illumina (ILMN) 218.57 6.59% 2022-10-05 14:58:44

The three biggest losers today are FedNat Holding Company, Lumen Technologies, and Enphase Energy.

Rank Financial Asset Price Change Updated (EST)
1 FedNat Holding Company (FNHC) 0.23 -23.02% 2022-10-05 15:14:06
2 Lumen Technologies (LUMN) 7.28 -9.51% 2022-10-05 14:52:38
3 Enphase Energy (ENPH) 261.36 -9.33% 2022-10-05 14:57:10
4 Cyclacel Pharmaceuticals (CYCCP) 7.01 -9.21% 2022-10-04 23:13:06
5 FuelCell Energy (FCEL) 3.45 -8% 2022-10-05 14:57:28
6 Annaly Capital (NLY) 17.41 -6.83% 2022-10-05 14:47:13
7 Brandywine Realty Trust (BDN) 6.49 -6.81% 2022-10-05 14:56:22
8 Dawson Geophysical Company (DWSN) 1.63 -6.32% 2022-10-05 04:41:15
9 Plug Power (PLUG) 21.92 -6.26% 2022-10-05 14:58:24
10 Celsius Holdings (CELH) 88.45 -6.25% 2022-10-05 14:47:44

Winners today

1. Curis (CRIS) – 17.2%

Curis, Inc. is a biotechnology firm that focuses on the development and discovery of drugs candidates to treat human cancers. The company’s first clinical-stage drug candidates are CA-4948 (an oral small molecule candidate for treatment of non-hodgkin and acute myeloid lymphomas and myelodysplastic disorders); and CI-8993 (a monoclonal antibody that antagonizes the V-domain Ig suppressor T cell activation) which is currently in Phase Ia/Ib clinical trials in patients with solid tumours. Fimepinostat is an oral dual inhibitor HDAC/PI3K enzymes that can be used to treat patients suffering from MYC-altered DLB-cell lymphoma or solid tumors. CA-170 is an oral small molecule candidate drug for patients who have advanced lymphomas and solid tumors. CA-327 is a pre-investigational drug stage candidate in oncology. F. Hoffmann-La Roche Ltd., Genentech Inc., have signed a collaboration agreement for Erivedge’s development and commercialization. This small-molecule signaling pathway inhibitor is administered orally to treat advanced basal cell carcinoma. Aurigene Discovery Technologies Limited has been contracted for the commercialization and development of small-molecule compounds in immuno-oncology, precision oncology, and precision oncology. It was founded in 2000. The headquarters are in Lexington, Massachusetts.

NASDAQ ended the session with Curis rising 17.2% to $0.82 on Wednesday, following the last session’s upward trend. NASDAQ slid 0.25% to $11,148.64, after two successive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Curis has a trailing twelve months EPS of $-0.615.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.17%.

Yearly Top and Bottom Value

Curis’s stock is valued at $0.82 at 17:32 EST, way below its 52-week high of $8.20 and way above its 52-week low of $0.68.

Moving Average

Curis’s worth is way under its 50-day moving average of $0.96 and way below its 200-day moving average of $1.91.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6%, now sitting on 10.52M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 41.7% and a negative 41.7%, respectively.

More news about Curis.

2. Citi Trends (CTRN) – 11.06%

Citi Trends, Inc. is a retailer that sells fashion accessories, apparel, and home products at a low price. It offers clothing for women and men, such as footwear and fashion sportswear for both men and women, as well for children, including babies, toddlers, girls, boys and girls, sleepwear, lingerie and scrubs for the ladies and uniforms for kids. Accessories and beauty products include bags, luggage, handbags and belts as well as jewelry and undergarments for both men and women. The company also offers lifestyle and home products that include products for bathroom, kitchen and decoration, food tech and products to help you stay healthy, seasonal products and books. The company’s products are primarily sold to Latinx and African American families within the United States. The company had 585 retail outlets in rural and urban markets across 33 states as of the 30th January 2021. The original name of the company was Allied Fashion, Inc., but it changed its name in 2001 to Citi Trends, Inc. Citi Trends, Inc. is located in Savannah, Georgia. It was established in 1946.

NASDAQ ended the session with Citi Trends rising 11.06% to $17.57 on Wednesday while NASDAQ fell 0.25% to $11,148.64.

Earnings Per Share

As for profitability, Citi Trends has a trailing twelve months EPS of $5.73.

PE Ratio

Citi Trends has a trailing twelve months price to earnings ratio of 3.07. Meaning,
the purchaser of the share is investing $3.07 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.71%.

Volume

Today’s last reported volume for Citi Trends is 183670 which is 25.68% below its average volume of 247145.

Moving Average

Citi Trends’s value is way below its 50-day moving average of $23.05 and way under its 200-day moving average of $34.87.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Citi Trends’s EBITDA is 0.41.

More news about Citi Trends.

3. Aspen Group (ASPU) – 9.93%

Aspen Group, Inc., a technology-based education company, offers online higher education in the United States. It offers certificates, bachelor’s and master’s degree programs, along with programs that can lead to doctoral degrees in business, technology and arts. It had 13 334 students who were pursuing degrees as of April 30, 2022. Aspen Group, Inc., was established in 1987. It is located in New York, New York.

NASDAQ ended the session with Aspen Group rising 9.93% to $0.43 on Wednesday, after two successive sessions in a row of gains. NASDAQ dropped 0.25% to $11,148.64, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.383.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.92%.

Yearly Top and Bottom Value

Aspen Group’s stock is valued at $0.43 at 17:32 EST, way under its 52-week high of $6.04 and way higher than its 52-week low of $0.33.

Moving Average

Aspen Group’s worth is way under its 50-day moving average of $0.81 and way below its 200-day moving average of $1.24.

Volatility

Aspen Group’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.11%, a negative 4.53%, and a positive 4.53%, respectively.

Aspen Group’s highest amplitude of average volatility was 1.56% (last week), 7.09% (last month), and 4.53% (last quarter), respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1.7%, now sitting on 76.69M for the twelve trailing months.

More news about Aspen Group.

4. Eagle Pharmaceuticals (EGRX) – 8.05%

Eagle Pharmaceuticals, Inc. is a US-based pharmaceutical company. It focuses on the development and commercialization of product candidates for diseases of central nervous systems or metabolic critical care, as well as oncology. Ryanodex is available for malignant heath; and Belrapzo and Bendeka are offered for chronic lymphocytic and non-Hodgkin’s lymphomas. EP-4104 is a dantrolene salt to treat organophosphates exposure. PEMFEXY is a ready to use/dilutive liquid pemetrexed form for small cell lung cancer. EA-114 (fulvestrant), for HR+/HER+ breast cancer. Vasopressin injection can be used to increase blood pressure in patients with vasodilatory stress. Combioxin, SA has a license agreement and collaboration agreements for the development of CAL02, an antibiotic agent to treat severe pneumonia. AOP Orphan Pharmaceuticals GmbH owns the rights for Landiolol, a new therapeutic product that can be used for the temporary reduction in ventricular rate for patients suffering from supraventricular tachycardia, atrial fibrillation, and atrial flutter. For the treatment of breast cancer (HR+/HER2-), and metastatic sarcomas at high risk, it has a partnership with Tyme Technologies, Inc. Eagle Pharmaceuticals, Inc., was established in 2007. It is located in Woodcliff Lake, New Jersey.

NASDAQ ended the session with Eagle Pharmaceuticals rising 8.05% to $26.99 on Wednesday, following the last session’s upward trend. NASDAQ fell 0.25% to $11,148.64, after two successive sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Eagle Pharmaceuticals has a trailing twelve months EPS of $1.64.

PE Ratio

Eagle Pharmaceuticals has a trailing twelve months price to earnings ratio of 16.46. Meaning,
the purchaser of the share is investing $16.46 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.53%.

More news about Eagle Pharmaceuticals.

5. Cytosorbents Corporation (CTSO) – 7.86%

Cytosorbents Corporation is a company that specializes in critical care immunotherapy. It focuses on the development and marketing of medical devices using its blood purification platform. This technology platform incorporates a proprietary porous polymer and adsorbent technology. CytoSorb is its flagship product. It provides extracorporeal and adjunctive therapies in sepsis and other critical conditions. VetResQ is a tool for treating sepsis, diabetes, and other serious illnesses in animals. CytoSorbXL, which can be used to treat sepsis in addition to other conditions, has been developed by the company. K+ontrol, for severe hyperkalemia treatment in patients who have life-threatening medical conditions, uses ContrastSorb to remove IV contrast from blood during CT imaging or angiograms to decrease the chance of developing contrast-induced renal disease. It is also involved in developing BetaSorb which prevents and treats health problems caused by chronic renal failure patients. DrugSorb removes toxic chemicals from blood. The firm was previously known as MedaSorb Technologies Corporation. In May 2010, it changed its name from Cytosorbents Corporation. Cytosorbents Corporation is located in Monmouth Junction in New Jersey. It was established in 1997.

NASDAQ ended the session with Cytosorbents Corporation rising 7.86% to $1.51 on Wednesday, after three sequential sessions in a row of gains. NASDAQ fell 0.25% to $11,148.64, after two consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Cytosorbents Corporation has a trailing twelve months EPS of $-0.68.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -58.32%.

More news about Cytosorbents Corporation.

6. Bionano Genomics (BNGO) – 7.6%

Bionano Genomics, Inc. offers genome analysis software. Saphyr is a sample to result solution for structural variation analysis using optical genome mapping. It also offers Saphyr (a single-molecule imaging device); Saphyr Chip (a consumable that packs the nanochannel arrays in order for DNA linearization); and Bionano Prep Kits, and DNA Labeling Kits, which offer the necessary reagents, protocols, and protocols for labeling high-molecular-weight DNA. Saphyr, Bionano and NxClinical are also available. These servers allow for the analysis and interpretation genomic variants created by microarrays as well as next-generation sequencing data. It also offers laboratory and testing services, including FirstStepDx Plus, a chromosomal Microarray to determine an underlying cause of autism spectrum disorder and developmental delay in people with intellectual disabilities; Fragile X (FXS), testing services; NextStepDx plus, an exome sequencing test that identifies genetic variants associated with childhood disorders; EpiPanelDx P, a panel for genetic testing for children who have suffered seizures, infantile spasms or encephalopathy; and PGx, which identifies more than 60 genes. It was established in 2003 in San Diego.

NASDAQ ended the session with Bionano Genomics jumping 7.6% to $2.20 on Wednesday, following the last session’s upward trend. NASDAQ fell 0.25% to $11,148.64, after two successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Bionano Genomics has a trailing twelve months EPS of $-0.394.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.43%.

Volume

Today’s last reported volume for Bionano Genomics is 18133100 which is 134.09% above its average volume of 7745920.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 28.6% and a negative 28.6%, respectively.

Yearly Top and Bottom Value

Bionano Genomics’s stock is valued at $2.20 at 17:33 EST, way below its 52-week high of $6.28 and way higher than its 52-week low of $1.16.

More news about Bionano Genomics.

7. 8×8 (EGHT) – 7.23%

8×8, Inc. provides voice, video, chat, contact center, and enterprise-class application programmable interface (API) Software-as-a-Service solutions for small and mid-size businesses, mid-market and larger enterprises, government agencies, and other organizations worldwide. It offers services such as unified communications and team collaboration. It provides 8×8 Work, a self-contained end-to-end united communications solution that delivers enterprise voice with public switched telephone network connectivity, video meetings, and unified messaging, as well as direct messages, public and private team messaging rooms, and short and multimedia services; 8×8 Contact Center, a multi-channel cloud-based contact center solution; and 8×8 CPaaS, a set of global communications Platform-as-a-Service. It also provides X1 throughX4 as well as X5 to X8 which offer enterprise-grade voice and unified communications. The company markets its services through third-party leads, search engine optimization, industry conferences and trade shows. It was founded in 1987 in Campbell, California.

NASDAQ ended the session with 8×8 jumping 7.23% to $3.71 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ slid 0.25% to $11,148.64, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, 8×8 has a trailing twelve months EPS of $-1.547.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -108.52%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

8×8’s EBITDA is -81.25.

Moving Average

8×8’s worth is way below its 50-day moving average of $4.62 and way below its 200-day moving average of $9.32.

Yearly Top and Bottom Value

8×8’s stock is valued at $3.71 at 17:33 EST, way below its 52-week high of $24.81 and way higher than its 52-week low of $3.18.

More news about 8×8.

8. Schlumberger (SLB) – 7.08%

Schlumberger Limited is a global provider of technology to the energy sector. It operates in four segments: Digital & Integration; Reservoir Performance; Well Construction and Production Systems. The company offers IT infrastructure, software and information management services. It also provides consulting services to reservoir characterization and field development planning. It also offers mud logging and engineering support services; drilling machinery and equipment for energy companies and shipyards; drilling tools and land drilling rigs; well cementing products; and well drilling and drilling. The company designs, manufactures, markets, and manages engineered drilling fluid system. It also offers well completion and equipment, artificial lift production equipment, optimization services, valves and process systems. The company can design and produce onshore and offshore wellhead systems as well as processing solutions. The firm was formerly called Societe’de Prospection Electro’lectrique. Schlumberger Limited was established in Houston, Texas in 1926.

NYSE ended the session with Schlumberger jumping 7.08% to $41.89 on Wednesday, after four consecutive sessions in a row of gains. NYSE dropped 0.4% to $14,262.03, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Schlumberger has a trailing twelve months EPS of $-2.04.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.94%.

Volatility

Schlumberger’s last week, last month’s, and last quarter’s current intraday variation average was 2.67%, 0.03%, and 2.50%, respectively.

Schlumberger’s highest amplitude of average volatility was 2.79% (last week), 2.86% (last month), and 2.50% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Schlumberger’s stock is considered to be oversold (<=20).

More news about Schlumberger.

9. Cavco Industries (CVCO) – 6.66%

Cavco Industries, Inc. is a manufacturer and retailer of manufactured homes, primarily in America. The company operates in two areas: Factory-Built Housing and Financial Services. It sells manufactured homes under the brands Cavco, Fleetwood Palm Harbor, Fairmont and Friendship. The company also makes park-model RVs and vacation homes. It also produces factory-built commercial structures such as apartment buildings, condos, hotels and condominiums. The company also produces modular homes. These include Cape Cod, ranch style, split-level and single-section homes. It also makes multi-family homes under the Nationwide Homes brand. It also offers conforming and non-conforming mortgages and home-only loans for purchasers of different brands of factory-built houses sold in company-owned retail shops as well as independent distributors and builders. The company also offers homeowners of manufactured homes property and casualty coverage. It owned 40 retail outlets in Oregon, Arizona and New Mexico. It also distributes homes via a network independent distribution points throughout 43 states and Canada, as well through residential developers and planned community operators. Cavco Industries, Inc. is located in Phoenix, Arizona.

NASDAQ ended the session with Cavco Industries rising 6.66% to $228.84 on Wednesday while NASDAQ fell 0.25% to $11,148.64.

Earnings Per Share

As for profitability, Cavco Industries has a trailing twelve months EPS of $6.83.

PE Ratio

Cavco Industries has a trailing twelve months price to earnings ratio of 33.5. Meaning,
the purchaser of the share is investing $33.5 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.11%.

Moving Average

Cavco Industries’s worth is under its 50-day moving average of $240.69 and below its 200-day moving average of $247.88.

Yearly Top and Bottom Value

Cavco Industries’s stock is valued at $228.84 at 17:33 EST, way below its 52-week high of $327.24 and way above its 52-week low of $179.47.

Revenue Growth

Year-on-year quarterly revenue growth grew by 64.9%, now sitting on 1.63B for the twelve trailing months.

More news about Cavco Industries.

10. Illumina (ILMN) – 6.59%

Illumina, Inc. offers array- and sequencing-based solutions to genetic and genomic analysis. Illumina’s services and products are available to customers across a variety of markets. They enable the use of genomic solutions for research and clinical applications. These include the areas of life science, oncology and reproductive health. It offers consumables and instruments for genetic analysis, genotyping, sequencing, contract service contracts, development and licensing agreements as well as services in cancer detection and testing. Customers include academic and government institutions as well as hospitals and pharmaceutical and biotechnology companies. It sells directly to its customers in North America and Europe as well as Latin America and the Asia-Pacific. It was founded in 1998 in San Diego, California.

NASDAQ ended the session with Illumina rising 6.59% to $218.57 on Wednesday while NASDAQ dropped 0.25% to $11,148.64.

Earnings Per Share

As for profitability, Illumina has a trailing twelve months EPS of $4.28.

PE Ratio

Illumina has a trailing twelve months price to earnings ratio of 51.07. Meaning,
the purchaser of the share is investing $51.07 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.86%.

More news about Illumina.

Losers Today

1. FedNat Holding Company (FNHC) – -23.02%

FedNat Holding Company and its affiliates are involved in insurance distribution and underwriting in Florida, Louisiana and Texas. It is also involved in homeowners and casualty, personal auto insurance and commercial general liability. The company markets and distributes products from its own insurers and those of third-party insurance companies. It also offers other services via a network independent agents and general agents. Federated National Holding Company was the company’s former name. FedNat Holding Company took over its operations in May 2018 and became FedNat Holding Company. FedNat Holding Company is located in Sunrise, Florida. It was established in 1991.

NASDAQ ended the session with FedNat Holding Company dropping 23.02% to $0.23 on Wednesday, following the last session’s downward trend. NASDAQ slid 0.25% to $11,148.64, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, FedNat Holding Company has a trailing twelve months EPS of $-7.318.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -158.31%.

Moving Average

FedNat Holding Company’s worth is way below its 50-day moving average of $0.33 and way under its 200-day moving average of $0.77.

More news about FedNat Holding Company.

2. Lumen Technologies (LUMN) – -9.51%

Lumen Technologies, Inc. is a technology-based communications and technology company that provides integrated products and services to residential and business customers across the United States. It operates in two markets: Mass Markets and Business. The company offers cloud and application services such as colocation and server services, managed security services and content delivery services. It also provides IP and data services including Ethernet, VPN, Internet Protocol (IP) and voice over the internet protocol. It also offers fiber infrastructure services, which include high-bandwidth optical wavelength networks and unlit optic fiber. It also offers voice and other services. This includes private line services that are specifically designed to connect two or more organizations; traditional time division multiplexing voice service portfolios; and synchronous optical network based Ethernet and legacy data hosting. The company had approximately 4.5million broadband subscribers as of December 31, 2021. The former name of the company was CenturyLink, Inc., but it changed its name in September 2020 to Lumen Technologies, Inc. Lumen Technologies, Inc. is located in Monroe, Louisiana.

NYSE ended the session with Lumen Technologies dropping 9.51% to $7.28 on Wednesday, after four sequential sessions in a row of gains. NYSE slid 0.4% to $14,262.03, after two consecutive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Lumen Technologies has a trailing twelve months EPS of $-0.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.68%.

Yearly Top and Bottom Value

Lumen Technologies’s stock is valued at $7.28 at 17:33 EST, way under its 52-week low of $9.31.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Lumen Technologies’s stock is considered to be oversold (<=20).

Volatility

Lumen Technologies’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.15%, a negative 1.21%, and a positive 1.95%, respectively.

Lumen Technologies’s highest amplitude of average volatility was 4.73% (last week), 2.76% (last month), and 1.95% (last quarter), respectively.

Sales Growth

Lumen Technologies’s sales growth is negative 6.8% for the present quarter and negative 8.1% for the next.

More news about Lumen Technologies.

3. Enphase Energy (ENPH) – -9.33%

Enphase Energy, Inc., along with its subsidiaries, design, develop, manufacture, and market home energy solutions to the solar photovoltaic sector in the United States. It offers a semiconductor-based microinverter that converts solar energy to individual modules. The software is combined with proprietary networking and software technology to offer energy control and monitoring services. The company also sells AC battery storage, Envoy communication gateway and Enlighten cloud-based monitor service. It sells solutions directly to homeowners and solar distributors. Enphase Energy, Inc., was founded in 2006 in Fremont, California.

NASDAQ ended the session with Enphase Energy falling 9.33% to $261.36 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ dropped 0.25% to $11,148.64, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Enphase Energy has a trailing twelve months EPS of $0.67.

PE Ratio

Enphase Energy has a trailing twelve months price to earnings ratio of 388.35. Meaning,
the purchaser of the share is investing $388.35 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 39.25%.

Sales Growth

Enphase Energy’s sales growth is 71.8% for the present quarter and 57.6% for the next.

Volatility

Enphase Energy’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.37%, a positive 0.16%, and a positive 2.93%, respectively.

Enphase Energy’s highest amplitude of average volatility was 2.30% (last week), 2.82% (last month), and 2.93% (last quarter), respectively.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 71.7% and 49.3%, respectively.

More news about Enphase Energy.

4. Cyclacel Pharmaceuticals (CYCCP) – -9.21%

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company in clinical stage. It develops drugs for cancer treatment and other proliferative conditions. Oncology programs at the company include fadraciclib (a cyclin dependent kinase inhibitors) which is currently in Phase 1 clinical trials for treatment of solid tumors. It can also be used in conjunction with venetoclax for the treatment relapsed/refractory chronic Lymphocytic Leukemia. CYC140 is a pololike kinase inhibitor program that is in phase I clinical trials for advanced leukemias. Sapacitabine is an oral prodrug for CNDAC that can be taken orally. This novel nucleoside analog also makes up the company’s oncology programs. The company also offers seliciclib as a CDK inhibitor in its oncology programs. The company has an agreement of clinical collaboration with the University of Texas MD Anderson Cancer Center for clinical evaluation of the safety and effectiveness of three cyclacel medicines among patients suffering from hematological malignancies. This includes chronic lymphocytic, acute myeloid, myelodysplastic, and other advanced forms of leukemias. Cyclacel Pharmaceuticals, Inc., was established in 1992. It is located in Berkeley Heights, New Jersey.

NASDAQ ended the session with Cyclacel Pharmaceuticals dropping 9.21% to $7.01 on Wednesday while NASDAQ fell 0.25% to $11,148.64.

Earnings Per Share

As for profitability, Cyclacel Pharmaceuticals has a trailing twelve months EPS of $-2.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.66%.

More news about Cyclacel Pharmaceuticals.

5. FuelCell Energy (FCEL) – -8%

FuelCell Energy, Inc., along with its subsidiaries, design, manufacture, sell, install, operate, and service stationary fuel cells power plants for distributed baseload generation. SureSource1500 is a platform with a 1.44 megawatt (MW), SureSource 3000 is a platform with a 2.38 MW; SureSource 4000 is a platform at 3.7 MW; SureSource 25000 has a 250-kilowatt platform and SureSource 400 has a 400-kW platform. SureSource Hydrogen (a platform of 2.3MW) can produce as much as 1,200 kgs per day to power distributed baseload hydrogen, utility and microgrid applications. The SureSource Capture system separates and concentrates carbon dioxide in the flue gas of natural gas, biomass or coal-fired power stations. It can also be used to produce hydrogen for industrial applications; solid oxide fuel cells/solid oxide stack technology. SureSource power plants from the company produce clean electricity, heatable water, hydrogen, and usable heat. In addition, it provides engineering, procurement, and construction services; project financing services; and real-time monitoring and remote operation, online support system, preventative maintenance, parts and supplies, on-site and classroom training, and power plant refurbishment/recycling services, as well as technical services in the areas of plant operation and performance, and fuel processing. The company serves many markets including utility and independent power producers as well as industrial and process applications. It also provides data centers and communications, health care, education, healthcare, information, waste treatment, commercial and hospitality, wastewater treatment, government microgrids, food, beverage and other foods and beverages. It primarily operates in South Korea, England and Germany. FuelCell Energy, Inc., was established in 1969. Its headquarters are in Danbury, Connecticut.

NASDAQ ended the session with FuelCell Energy dropping 8% to $3.45 on Wednesday, after three consecutive sessions in a row of gains. NASDAQ fell 0.25% to $11,148.64, after two sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, FuelCell Energy has a trailing twelve months EPS of $-0.399.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.91%.

Yearly Top and Bottom Value

FuelCell Energy’s stock is valued at $3.45 at 17:34 EST, way below its 52-week high of $11.63 and way higher than its 52-week low of $2.87.

More news about FuelCell Energy.

6. Annaly Capital (NLY) – -6.83%

Annaly Capital Management, Inc. is a multi-faceted capital manager that specializes in corporate and mortgage financing. It invests in mortgage servicing rights, agency mortgage-backed security, commercial mortgage-backed Securities, Agency residential mortgage assets, residential loans, credit risk transfer securities and corporate debts. The company has chosen to be treated as a real-estate investment trust (REIT) tax. It is exempt from federal income taxes if it pays its shareholders its taxable income as a REIT. It was established in New York in 1996.

NYSE ended the session with Annaly Capital dropping 6.83% to $17.41 on Wednesday, after two sequential sessions in a row of gains. NYSE dropped 0.4% to $14,262.03, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Annaly Capital has a trailing twelve months EPS of $3.1.

PE Ratio

Annaly Capital has a trailing twelve months price to earnings ratio of 5.61. Meaning,
the purchaser of the share is investing $5.61 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.95%.

Volume

Today’s last reported volume for Annaly Capital is 15050600 which is 57.64% above its average volume of 9547020.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jun 28, 2022, the estimated forward annual dividend rate is 0.88 and the estimated forward annual dividend yield is 12.79%.

More news about Annaly Capital.

7. Brandywine Realty Trust (BDN) – -6.81%

Brandywine Realty Trust, NYSE: BDN, is one of America’s largest, most publicly traded, fully-service, integrated realty companies. Its core markets are Philadelphia, Austin, and Washington, D.C. As a real-estate investment trust (REIT), our portfolio includes 175 properties, 24.7 million square feet, and is currently being developed, leased, and managed by us. This excludes any assets that may be sold. Through our knowledge, relationships, communities we create, and the stories we share, we aim to influence, connect, and inspire the world.

NYSE ended the session with Brandywine Realty Trust dropping 6.81% to $6.49 on Wednesday, after three successive sessions in a row of gains. NYSE slid 0.4% to $14,262.03, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Brandywine Realty Trust has a trailing twelve months EPS of $1.78.

PE Ratio

Brandywine Realty Trust has a trailing twelve months price to earnings ratio of 3.64. Meaning,
the purchaser of the share is investing $3.64 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.96%.

More news about Brandywine Realty Trust.

8. Dawson Geophysical Company (DWSN) – -6.32%

Dawson Geophysical Company offers onshore processing and data acquisition services throughout the United States. It processes multi-component, 2-D and 3-D seismic data on behalf of its clients. This includes independent oil and natural gas operators and oil companies. The company’s seismic crews provide seismic data to companies involved in exploration and development on- and off-shore of natural gas and oil in transition zones. It also provides services to the potash mine industry. Dawson Geophysical Company was established in Midland, Texas in 1952. Wilks Brothers, LLC is the parent company of Dawson Geophysical Company.

NASDAQ ended the session with Dawson Geophysical Company falling 6.32% to $1.63 on Wednesday while NASDAQ dropped 0.25% to $11,148.64.

Earnings Per Share

As for profitability, Dawson Geophysical Company has a trailing twelve months EPS of $-0.564.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.91%.

Volume

Today’s last reported volume for Dawson Geophysical Company is 9725 which is 2.65% below its average volume of 9990.

Yearly Top and Bottom Value

Dawson Geophysical Company’s stock is valued at $1.63 at 17:34 EST, way below its 52-week high of $2.69 and way above its 52-week low of $1.08.

More news about Dawson Geophysical Company.

9. Plug Power (PLUG) – -6.26%

Plug Power Inc. provides end-to-end hydrogen and zero emission fuel cell solutions to supply chain and logistics, on-road electric cars, the stationary power market and other markets in North America as well as internationally. The company is involved in the creation of a green hydrogen ecosystem that includes green hydrogen storage, delivery and production as well as energy generation via mobile and stationary devices. It offers fuel cell and battery hybrid technologies as well as fuel cell/battery and proton exchange membrane (PEM), and fuel cell and fuel processor technologies. GenDrive is a hydrogen-fueled, PEM fuel-cell system, which provides power for material handling electric cars; GenFuel is a liquid fueling delivery system, storage, dispensing and storage system. GenCare offers an on-site maintenance program that uses the Internet of Things to maintain and service GenDrive fuel cells systems, GenSure fuel cells systems, GenFuel fuel cell products and engines, as well as GenDrive and GenSure stationary fuel cells. This solution offers PEM fuel cell power, utility sector’s. GenKey is a turn-key integrated solution to transition to fuel cell power. It also offers ProGen, which is a fuel cells stack and engine technology that can be used in stationary and mobility fuel cell systems and in engines for electric delivery vans. GenFuel Electrolyzers are hydrogen generators specifically designed for clean hydrogen production. It sells products via a direct sales force, original equipment makers, and dealer networks. The company has agreements with Airbus, Lhyfe, Edison Motors and Phillips 66. It also works with Apex Clean Energy, BAE Systems and Universal Hydrogen Co. It was established in 1997. The company is located in Latham in New York.

NASDAQ ended the session with Plug Power sliding 6.26% to $21.92 on Wednesday, after two sequential sessions in a row of gains. NASDAQ slid 0.25% to $11,148.64, after two sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Plug Power has a trailing twelve months EPS of $-1.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.83%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 95.7%, now sitting on 571.19M for the twelve trailing months.

Volume

Today’s last reported volume for Plug Power is 18455500 which is 13.72% below its average volume of 21392400.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 11.1% and positive 10.5% for the next.

More news about Plug Power.

10. Celsius Holdings (CELH) – -6.25%

Celsius Holdings, Inc. produces, markets, distributes, sells and services liquid supplements and functional drinks in North America, Europe, Asia, the Middle East, and beyond. Under the CELSIUS Originals brand, it offers a variety of carbonated and uncarbonated functional energy beverages; a dietary supplement with carbonated flavors including blueberry pomegranate and strawberry dragon fruit under the CELSIUS Heat name; and functional energy drink with branched chain amino acids that aids in muscle recovery under CELSIUS BCCA+ENERGY. CELSIUS ON-the-GO, which is a powdered version of active ingredients found in functional energy beverages, can be purchased in On-The-Go containers and individual packets. There are also sparkling grapefruit, cucumber lime and orange pomegranate as well as non-carbonated functional drinks such as CELSIUS sweetened, pineapple coconut and watermelon. Direct-to-store distribution distributors distribute its products. In January 2007, Celsius Holdings, Inc. was established. Celsius Holdings, Inc., was established in 2004. It is located in Boca Raton, Florida.

NASDAQ ended the session with Celsius Holdings falling 6.25% to $88.45 on Wednesday while NASDAQ slid 0.25% to $11,148.64.

Earnings Per Share

As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.11.

PE Ratio

Celsius Holdings has a trailing twelve months price to earnings ratio of 804.09. Meaning,
the purchaser of the share is investing $804.09 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.95%.

Sales Growth

Celsius Holdings’s sales growth is 123.9% for the present quarter and 68% for the next.

More news about Celsius Holdings.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here